This study looks at how a medicine called LY3209590 is processed in the bodies of young people with Type 2 Diabetes Mellitus (T2DM). T2DM is a condition where the body has trouble using insulin, a hormone that helps control blood sugar. The study will last for about 100 days, and participants will receive a single dose of LY3209590.

Eligibility: To join, participants must have had T2DM for at least 3 months, a specific blood sugar level (HbA1c between 6.5% and 9.5%), and a body mass index (BMI) of 45.0 kg/m² or less. They should not have used insulin in the last 3 months.

Exclusion: Those who have had severe low blood sugar, kidney problems, recent major weight changes, cancer, or recent blood transfusions cannot participate. Also, if they are taking certain medications or are part of another study, they cannot join.

• The study duration is approximately 100 days.
• Participants will need to visit the study site for tests and monitoring.
• Potential risks include side effects from the medication.